Morningstar Investor users sign in here.

Video

Analyst insights: 2 retail stocks set to defy gloomy outlook

Households are expected to tighten their spending in 2023 as higher interest rates bite, but there are opportunities on the ASX in the retail sector according to Morningstar's Johannes Faul.

Mentioned: Domino's Pizza Enterprises Ltd (DMP), Kogan.com Ltd (KGN)


Transcript:

Johannes Faul: The key theme really for the retailing sector heading into the next year is that we're expecting a slowdown in sales growth across the sector, and what's really driving that is not the consumer becoming weaker. We actually don't expect household spending in total to really collapse just given the high amount of savings that Australians have accumulated. So, what's going to make retail sales weaken, in our opinion, is just the shift from what people are going to spend on. They're going to spend more on services and less on goods. Most likely, they're going to spend more on things like rent, transport, electricity, things like that, and basically, divert the expenditures away from retailing, away from goods and into services. That's our expectation for the new year overall for retailers is that we expect the top-line growth to be nothing like F '22, and that's going to have an impact on profits and also the profitability of sales. So, that's our outlook for the sector in general.

Yes, the two stocks we see as undervalued at the moment is Kogan (KGN), that's our top pick in the sector and also, Domino's Pizza (DMP), which is also undervalued at the moment. And we just spoke about momentum slowing heading into 2023 for retailing sales. But for these two companies, we've already seen that happen. And on the back of that their share prices have come off dramatically, from being, in our opinion, overvalued to now being undervalued.

What we've seen for Kogan? It's a pure online retailer with all the stores that we see, the physical stores, brick and mortar stores reopening, people have shopped a lot less online, which means a lot less online sales and that has impacted Kogan. So, their top-line has been shrinking. That has impacted profits. But we see change in 2023 and basically, Kogan to establish a maintainable level of sales. So, that decline we've seen in sales, that's going to stop, and it's going to start growing again gradually from a rebased level. And that means profits are going to come back, and that's what we see as the catalyst for the share price of Kogan to rerate.

For Domino's, they're a big international franchisee selling pizzas. And again, during COVID, they've done really, really well. People love pizzas, especially in Japan. That growth has slowed in some jurisdictions. They've actually seen sales come down. At the same time, a lot of the ingredients for pizzas unfortunately have gone up by quite a bit. So, the inflation we're seeing as customers in the retail stores, Domino's is seeing on the cost side, where if you think about labor, but especially ingredients like cheese and the like. So, near term, that's a headwind for their earnings. But what really matters for Domino's valuation and what we see attractive for investors is a long-term pipeline. It's the solid pipeline of a lot more stores being rolled out globally, I should say, and that will continue. That's not really been impacted by this near-term cyclical weakness. So, for Domino's, as I say, that cyclical weakness we've seen is a great opportunity for investors to have a look at it at a company that has a moat and has a lot of growth ahead of it over the next decade.



© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Bank results: the winners and losers
Video

Bank results: the winners and losers

Morningstar analyst Nathan Zaia explains how the banks did and what the future holds.
How to deal with financial stress
Video

How to deal with financial stress

More high-income earners are now also experiencing financial stress. We go through practical ways to reduce it
UniSuper CIO John Pearce on why the 60/40 portfolio is far from dead
Video

UniSuper CIO John Pearce on why the 60/40 portfolio is far from dead

The $130 Billion SuperFund Manager also talks about how he sees risk, his recent investments, and why history isn’t a good guide to the future.
Incitec Pivot: explosive upside ahead?
Video

Incitec Pivot: explosive upside ahead?

Morningstar analyst Mark Taylor believes imminent growth in explosives earnings could lift sentiment.
Why Morningstar see opportunities in coal stocks
Video

Why Morningstar see opportunities in coal stocks

Analyst Jon Mills explains why he’s recently increased fair value estimates for Australian coal companies.
Is the sharp fall in ResMed's share price justified?
Video

Is the sharp fall in ResMed's share price justified?

The potential for weight loss drugs to impact the sleep apnea giant has weighed on the share price, though Morningstar analyst Shane Ponraj thinks...